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Statement of translational relevance  46 
Despite the wide range of therapies approved for treatment of breast cancer, 47 
mortality of patients due to metastatic spread has not been yet been addressed. 48 
The development of metastasis targeting treatments is essential in decreasing 49 
breast cancer related deaths in long term. Here we describe a vaccine based 50 
therapeutic approach targeting tumor antigen Cripto-1 expressed on tumor cells. 51 
We show that vaccination with Cripto-1 encoding DNA elicits an anti-Cripto-1 52 
directed immune response that consequently controls metastasis. Cripto-1 53 
expression has also been found on cancer stem cell like cells. Cancer stem cells 54 
are highly resistant to chemo and radiotherapy. They can be the cause for 55 
relapse and metastases due to their persistence after standard treatment. The 56 
anti-Cripto-1 directed immune response was able to eliminate cancer stem cells. 57 
Taken together, our data shows great potential of targeting tumor associated 58 
antigen Cripto-1 in controlling metastasis and eliminating cancer stem cells.  59 
 60 
61 
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Abstract 62 
Purpose: Metastatic breast cancer is a fatal disease responding poorly to 63 
classical treatments. Cancer vaccines targeting antigens expressed by metastatic 64 
breast cancer and cancer stem cells have the potential to become potent anti-65 
cancer therapies. Cripto-1 is an onco-fetal protein frequently overexpressed in 66 
invasive breast cancer and cancer-initiating cells. In this study, we explored the 67 
potential of a Cripto-1 encoding DNA vaccination to target breast cancer in 68 
preclinical models.  69 
Experimental Design: BALB/c mice and BALB-neuT mice were treated with a 70 
DNA vaccine encoding for mouse Cripto-1 (mCr-1). Mice were challenged with 71 
murine breast cancer 4T1 cells or TUBO spheres, or spontaneously developed 72 
breast cancer in the BALB-neuT model. Tumor growth was followed in all mouse 73 
models and lung metastases were evaluated. In-vitro assays were performed to 74 
identify the immune response elicited by vaccination.   75 
Results: Vaccination against mCr-1 reduced primary tumor growth in the 4T1 76 
metastatic breast cancer model and significantly reduced lung metastatic 77 
burden. The primary tumors in the BALB-neuT model are Cripto-1 negative. 78 
Consequently, we did not observe protection regarding the primary tumors. 79 
However, vaccination significantly reduced lung metastatic burden in this model. 80 
Spheroid cultured TUBO cells, derived from a BALB/neuT primary tumor, obtain 81 
cancer stem cell like phenotype and upregulate m-Cr-1. We observed reduced 82 
tumor growth in vaccinated mice after challenge with TUBO spheres.  83 
Discussion: Our data indicates that vaccination against Cripto-1 results in a 84 
protective immune response against mCr-1 expressing and metastasizing 85 
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tumors. Targeting Cripto-1 by vaccination is a promising potential 86 
immunotherapy for treatment of metastatic breast cancer. 87 
 88 
 89 
Introduction 90 
Breast cancer is the most common cancer among women in western countries 91 
and incidence rates have been rising in developing countries in the last years (1). 92 
Breast cancer is a heterogeneous disease and understanding molecular 93 
dysregulations has resulted in identification of novel therapeutic targets. The 94 
development of kinase inhibitors and Her2 targeting monoclonal antibodies led 95 
to increased survival rates among breast cancer patients, in particular in patients 96 
with local disease (2). However, relapse and metastases remain a hurdle to 97 
therapy and are the most common causes of death among women with breast 98 
cancer (3). Metastases derive from disseminated tumor cells, where epithelial 99 
mesenchymal transition (EMT) is a required process for the occurrence of 100 
metastasis at distant sites (4). Which cells in particular undergo this process and 101 
have greater potential to metastasize is not fully understood. Cancer stem cells 102 
(CSC) have been proposed to be one source of metastasis in breast cancer, and 103 
circulating tumor cells in patients with metastatic breast cancer express EMT 104 
markers and display a stem cells phenotype (5,6).            105 
In recent years, immunotherapy has become of interest in cancer therapy and 106 
has been successfully used to treat metastatic disease (7). The term 107 
immunotherapy summarizes diverse modalities of immune-based treatments, 108 
including checkpoint blockade, vaccines and adoptive transfer of immune cells. 109 
Checkpoint blocking antibodies targeting PD-1 and CTLA-4 are currently in 110 
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clinical trials (NCT02129556, NCT02892734) for metastatic breast cancer. 111 
CTLA-4 and PD-1 blockade exhibits two distinct mechanisms of action with PD-1 112 
blockade restoring function of anergic T cells and CTLA-4 expanding the T cells 113 
repertoire (8).         114 
Until now, therapeutic vaccines in cancer have been less successful. The success 115 
of antitumor vaccines is highly dependent on the choice of antigen and co-116 
stimulating agents as well as mode of delivery (9). Vaccines have the great 117 
potential to boost pre-existing anti-tumor immunity, and to activate tumor 118 
eliminating effector cells.   For breast cancer, several different vaccines targeting 119 
Her2 are currently in clinical trials (NCT01570036, NCT01152398, 120 
NCT02276300, NCT00194714), and we have conducted a pilot trial with a full 121 
length non-transforming Her2 DNA (10). For treatment of metastatic breast 122 
cancer, it is of particular interest to target antigens expressed on CSC and 123 
metastasizing cells. 124 
Cripto-1 (Cr-1) is an onco-fetal protein re-expressed in the majority of human 125 
tumors, including breast cancer (11). In breast cancer, Cr-1 expression in tumor 126 
cells is negatively correlated with survival (12). Cr-1 is a GPI-anchored cell 127 
surface protein essential in embryonic development. The protein co-localizes 128 
with several receptors and is involved in Nodal, TGFβ, and Wnt/βcatenin 129 
signaling among others (13). In tumors, Cr-1 has been shown to be involved in 130 
cell proliferation and migration, EMT and angiogenesis (14). In addition, Cr-1 131 
plays an important role in the maintenance of embryonic stem cells and is a 132 
target gene of the transcription factors Nanog and Oct4 in stem cells. Indeed, Cr-133 
1-positive cells were found to be Nanog- and Oct4-positive and able to form 134 
spheres in vitro (15). Studies on CSC in melanoma and prostate cancer have 135 
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shown that Cr-1 expression is associated with an undifferentiated phenotype 136 
(15,16). The expression of Cr-1 on CSC together with its role in intracellular EMT 137 
signaling makes it a potential antigen for metastasis and CSC targeting in breast 138 
cancer.  139 
We have previously shown that vaccination against Cr-1 elicits a protective 140 
immune response in C57BL/6 mice and results in reduced tumor burden upon 141 
subcutaneous challenge with murine melanomaB16F10 cells. Intravenous (i.v.) 142 
challenge with B16F10 in mice vaccinated with plasmids encoding murine Cr-1 143 
(pmCR) resulted in significant reduction of lung metastatic foci (17).          144 
Here we describe that vaccination induced an anti-Cr-1 directed humoral 145 
response that protects from metastasis burden in the aggressive orthotopic 4T1 146 
and the spontaneous BALB-neuT breast cancer mouse models.  Further, we show 147 
Cr-1 specific clearance of breast CSC in vivo. Anti-Cr-1 vaccination could 148 
potentially be of great benefit for patients with breast cancer, reducing the risk 149 
of relapse and disease progression.   150 
151 
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Material and methods 152 
Cell lines 153 
4T1 luciferase expressing cells (4T1) TS/A and D2F2 cell lines was maintained in 154 
RPMI 1640 supplemented with L-glutamine and 10% heat-inactivated FBS (Life 155 
technologies). TUBO cell line (18) was maintained in DMEM supplemented with 156 
20% FBS (Sigma-Aldrich). Murine Cripto-1(mCr-1)-expressing 4T1 (4T1mCr-1) 157 
cells were generated by transducing 4T1 cells with lentiviral particles (Amsbio).  158 
mCr-1-expressing cells were FACS sorted, see Flow cytometric analysis, and 159 
further selected with Geneticin (Life technologies). 160 
Spheroid culture 161 
TUBO and 4T1 single-cell suspensions were seeded in DMEM-F12 supplemented 162 
with 20 ng/ml EGF, 20 ng/ml FGF, 5 μg/ml insulin, 0.4 % BSA (Peprotech, Sigma 163 
Aldrich) at a concentration of 6 x 104 cells/ml in ultra-low attachment plates 164 
(Corning). The resulting spheroids were monitored daily and passed using 165 
enzymatic and mechanical dissociation every 3-5 days. Cells were re-seeded at 6 166 
x 104.  Spheroid cultures were passaged 3 times and passage 1 (P1), 2 (P2) and 3 167 
(P3) were collected for further experiments.  168 
Mice 169 
BALB/c mice were either purchased from ScanBur and maintained at the 170 
Department of Microbiology, Tumor and Cell Biology (Karolinska Institutet, 171 
Stockholm, Sweden) or bred and maintained at the Molecular Biotechnology 172 
Center (University of Torino, Torino, Italy). BALB-neuT mice were bred and 173 
maintained at the Molecular Biotechnology Center (University of Torino, Torino, 174 
Italy). Mice were handled in accordance to regional Animal ethics committees 175 
(Stockholms Norra Djurförsoksetiska Nämnd Avdelning 2, Sweden N426/11, 176 
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N239/14; University of Torino ethical committee authorization number 177 
837/2015-PR). 178 
Plasmid  179 
Mouse Cr-1(NM_011562.2) encoding plasmid was generously donated by Bianco 180 
C et al., (NCI NIH Bethesda) (19) and the coding sequence was subsequently 181 
cloned into the pVAX11 vector (Invitrogen) to obtain pmCr-1. pmCr-1 and 182 
pVAX11 were expanded in E.coli (TOP10, Invitrogen) grown in LB medium 183 
containing Kanamycin selection (50 μg/ml). Plasmids were purified using 184 
GigaPrep Endofree Kit (Qiagen).  185 
4T1mCr-1 orthotopic model 186 
BALB/c mice were vaccinated at 8 and 10 weeks of age by intradermal injection 187 
of 40 μg of plasmid in PBS followed by electroporation with plate electrodes 188 
(IGEA). Electroporation protocol has been previously described (17). In week 12, 189 
2x105 4T1mCr-1 cells diluted in 50 μl PBS were injected into the mammary fat 190 
pad. Tumors were measured by palpation twice per week and tumor volume was 191 
calculated using the formula (π/6) x L x W x H (20). Mice were sacrificed 3 weeks 192 
after tumor challenge and primary tumors were excised and weighed. Tumors 193 
were snap frozen in OCT. For lung colony formation assay, single-cell 194 
suspensions were prepared from harvested lungs, seeded in 15 cm dishes and 195 
cultured in RPMI supplemented with L-glutamine, 10% FBS, 1% PenStrep, 6-196 
Thioguanine (Sigma Aldrich). Medium was changed every 3-4 days. Upon colony 197 
formation, cells were fixed with 4% formaldehyde and stained with hematoxylin. 198 
Colonies were evaluated by counting. 199 
 BALB-neuT model 200 
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BALB-neuT mice were vaccinated with prime and boost at 10 and 12 weeks of 201 
age, respectively, by intramuscular injection of 50 μg of plasmid in saline. The 202 
injection was followed by electroporation using IGEA array needle electrode. 203 
Mice were inspected weekly for the presence of tumors, whose dimension was 204 
reported as mean tumor diameter. When mice reached a total number of 10 205 
mammary tumors, or a tumor reached a threshold size of 10 mm mean tumor 206 
diameter, mice were progressively culled, lungs were harvested and fixed in 207 
paraffin followed by staining with hematoxylin and eosin. Lung metastases were 208 
counted on a Nikon SMZ1000 stereomicroscope (Mager Scientific). The metastatic 209 
index was calculated by dividing the number of metastatic foci by the sum of the 210 
diameter of all primary lesions.  211 
TUBO P3 model 212 
BALB/c mice were vaccinated at 8 and 10 weeks of age by intramuscular 213 
injection of 50 μg plasmid in saline. The injection was followed by 214 
electroporation using IGEA array needle electrode. Two weeks after the second 215 
vaccination mice were challenged subcutaneously (s.c.) with 2x104 TUBO P3 216 
spheroids as described (21). Mice were inspected weekly for the presence of the 217 
tumor, whose dimension was reported as mean tumor diameter. Overall survival 218 
was reported as the time required by the tumor to reach the threshold of 10 mm 219 
mean tumor diameter, according to ethical guidelines.  220 
Antibodies 221 
See supplemental table 1. 222 
Serum 223 
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Serum was collected for analysis and in vitro studies 2 weeks after the second 224 
vaccination. Sera from all mice in each group within one experiment were 225 
pooled.  226 
Western Blot 227 
Cell lysates were prepared from fresh cell culture or snap frozen cell pellets 228 
stored at -80°C with 1 M RIPA buffer (150mM NaCl, 1% Triton-X 100, 0.5 % 229 
sodium deoxycholate, 0.1% SDS, 50 mM NaF, 50mM Tris-HCl ph 7.4)  and 1x 230 
protease (Roche). Protein concentrations were determined with Pierce BCA 231 
protein assay (Thermo Scientific) prior to loading onto gel. 20 μg protein lysates 232 
were reduced with 1x NUPAGE Reducing agent (Invitrogen) and 1x NuPage LDS 233 
Sample Buffer (Invitrogen) and loaded on 10% NuPAGE Bis-Tris acrylamide gels 234 
(Invitrogen). Proteins were transferred to PVDF membrane with methanol wet-235 
transfer. Primary antibodies were incubated overnight at 4°C and secondary 236 
antibodies for 1h at RT. Membranes were developed using Pierce ECL Western 237 
Blotting Substrate reagent kit. Luminescence was detected using LAS-1000 CCD 238 
camera system (Fujifilm, Tokyo, Japan).  239 
Flow cytometric analysis 240 
For flow cytometric analysis, single cell suspensions were prepared and 2x105 241 
cells were stained per sample. Cr-1 specific antibodies in serum of pmCr-1 242 
vaccinated mice were detected by cell surface staining of 4T1mCr-1 with serum 243 
from pmCR-1 vaccinated mice. For FACS sorting, transduced 4T1 cells were first 244 
stained with pmCr-1 serum and then with anti-mIgG-PE. pVAX1 serum was used 245 
as a negative control staining. For IgG subclass analysis, 4T1mCr-1 binding 246 
serum derived antibodies were detected with anti-mIgG-FITC, anti-mIgG1-FITC, 247 
anti-IgG2a-FITC and anti-IgG2b-FITC.  For unstained control, cells were only 248 
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stained with secondary antibodies. Percentage of IgG1, IgG2a and IgG2b were 249 
calculated by dividing mean fluorescent intensities (MFIs) by the sum of MFI for 250 
IgG1, IgG2a and IgG2b after subtraction of MFI of unstained cells. All samples 251 
were acquired either on LSRII (BD) or Novocyte (ACEA) and analyzed using 252 
FlowJo (Tree Star). 253 
In vivo imaging 254 
In vivo imaging was done with IVIS SpectrumCT (PerkinElmer) using D-Luciferin 255 
(Life Technologies).  5 µg D-Luciferin per gram mouse was injected i.p. and 256 
allowed to disseminate in the mouse for two minutes followed by anesthesia 257 
with Isoflurane at 3% for three minutes prior to transfer onto the heated, 37oC, 258 
SpectrumCT platform (Perkin Elmer) for imaging and analyzed using Living 259 
Image Software (Perkin Elmer).  260 
Lung colony assay 261 
Lungs from 4T1mCr-1 bearing mice were harvested and kept in cooled PBS 262 
supplemented with 10% FBS. Lungs were individually mechanically and 263 
enzymatically digested in RPMI supplemented with 5% FBS, 2 mg/ml Dispase, 264 
100 μg/ml DNase I, 200 μg/ml Collagenase IV for 30 min at 37oC. Cell suspension 265 
was filtered using a 70 μm filter (Fisher Scientific). Removal of red blood cells 266 
was done using RBC lysis buffer (BioLegend) and followed by suspension in 267 
supplemented RPMI-1640 media containing 6-Thioguanine (60 µM) and seeded 268 
in 150 mm cell culture dishes (Corning). After 10 days, cells were washed with 269 
PBS, followed by formaldehyde fixation and Hematoxylin Harris (VWR, 351945S) 270 
staining for 5 minutes. Primary tumors were excised and weighed. To evaluate 271 
lung metastasis, colonies were enumerated and metastatic index was calculated, 272 
MI = number of colonies/primary tumor weight.  273 
13 
 
Antibody dependent cellular cytotoxicity (ADCC) assay 274 
4T1mCr-1 and 4T1 cells were harvested and labeled with 51Cr (Perkin Elmer). 275 
After labeling, target cells were incubated for 10 minutes at 4°C with 10 µl of 276 
serum from pmCr-1 or pVAX1 vaccinated mice. 5x103 cells per well were then 277 
plated in 96-well plates without washing. wt BALB/c mice were sacrificed and 278 
splenocytes isolated. NK cells were purified with magnetic beads by DX5-positive 279 
selection (Miltenyi Biotech). NK cell fraction and negative fraction were titrated 280 
onto target cells. 25 l of co-culture supernatant were harvested after 4 and 16 h 281 
onto LUMA plates (Perkin Elmer). Radioactivity was detected in beta-counter 282 
(Perkin Elmer).  283 
Statistical analysis 284 
Data was analyzed with Prism 7 (GraphPad software). All in vivo data is shown 285 
as mean ± SD. Tumor growth, metastatic index and tumor growth rate were 286 
compared using Mann-Whitney test. Tumor weights were compared with 287 
unpaired t-test. Survival data were compared with log rank test. For NK cell 288 
cytotoxicity, 5 independent experiments are displayed and compared with 289 
paired t-test.  p-values < 0.05 were considered statistically significant.  290 
 291 
Results 292 
Vaccination with mouse Cripto-1-encoding DNA plasmid reduces metastatic 293 
burden and primary tumor growth in 4T1 metastasis model 294 
We aimed to understand if vaccination with pmCr-1 would elicit a protective 295 
immune response in a model of murine metastatic breast cancer. We screened 296 
four mouse mammary carcinoma cell lines on BALB/c background for Cr-1 297 
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expression by western blot. Weak bands of Cr-1 were found in 4T1, TUBO and 298 
TS/A, while D2F2 was negative for mCr-1 expression (Supplemental Fig. 1). As a 299 
first approach to establish the protective potential of mCr-1 vaccination-induced 300 
immune responses over the dissemination of mammary cancer cells in BALB/c 301 
models, we generated a stable mCr-1 expressing 4T1 transfectant (4T1mCr-1), 302 
which was used as a model for spontaneous lung metastasis (Supplemental Fig. 303 
1). BALB/c mice were vaccinated with pmCr-1 or control pVAX1 plasmids prior 304 
to implantation of 4T1mCr-1 cells into the mammary fat pad. Primary tumor 305 
growth was evaluated by in vivo luciferase activity detection at day 14 (Fig. 1A) 306 
and twice per week through palpation (Fig. 1B). At day 23 after tumor 307 
inoculation, mice were sacrificed and primary tumor weight measured (Fig. 1C). 308 
Primary tumor size and weight were significantly reduced in pmCR-1- compared 309 
to pVAX1-vaccinated mice. Furthermore, pmCR-1 vaccination greatly reduced 310 
spontaneous metastasis to the lungs as evaluated by a colony formation assay 311 
(Fig. 1D). Cr-1 vaccination results in anti-tumor immunity capable of controlling 312 
tumor growth and inhibiting metastatic spread.  313 
Cripto-1 specific humoral response 314 
It was previously shown that DNA vaccination in BALB/c mice can elicit a 315 
humoral response (22). We therefore evaluated the humoral response after 316 
vaccination with pmCR-1(23,24). Serum of pmCR-1-vaccinated mice was found 317 
to contain antibodies that stained specifically mCr-1 expressing 4T1 cells (Fig. 318 
2A), while no signal was observed on 4T1 cells. We found that the majority of 319 
these antibodies belonged to IgG2a and IgG2b subclasses (Fig. 2B). In mice, these 320 
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subclasses are responsible for mediating ADCC by NK cells, macrophages and 321 
neutrophils. 322 
  323 
Cripto-1 directed antibody dependent cellular cytotoxicity 324 
NK cells play a major role in the success of antibody-based immunotherapy. For 325 
several clinically successful therapeutic antibodies, including anti-Her2, anti-326 
EGFR and Anti-CD20, NK cells mediated cytotoxicity is a known mechanism of 327 
action (25).                                          328 
To confirm that Cr-1 specific antibodies can mediate ADCC, we tested if serum 329 
from pmCR-1-vaccinated mice increases cytotoxicity by NK cells. NK cells were 330 
purified from BALB/c splenocytes with magnetic bead selection and co-cultured 331 
with 4T1mCr-1 or 4T1 cells in the presence of pmCr-1 or pVAX1 serum. We 332 
found that pmCr-1 serum significantly increased lysis of 4T1mCR-1 cells by NK 333 
cells (Fig. 2C, D). No cytotoxic activity was detected by splenocytes depleted of 334 
NK cells (data not shown). To show that ADCC is Cr-1 specific we co-cultured NK 335 
cells with 4T1 cells in presence of serum from pmCr-1 and pVAX1 vaccinated 336 
mice. No difference in 4T1 lysis by NK cells was observed in presence of pmCr-1 337 
serum compared to pVAX1 serum (Fig. 2E). 338 
 339 
Reduced lung metastasis after vaccination in the BALB-neuT mouse model 340 
We additionally wanted to test if pmCr-1 vaccination has therapeutic effect in a 341 
more clinically relevant model (26). The BALB-neuT mouse model is genetically 342 
engineered to develop spontaneous cancerous lesions in the mammary tissue. 343 
We evaluated Cr-1 expression in the breast tumors of the model and only found 344 
low expression in tumors of 8 mm mean diameter (Suppl. Fig. 2) with no Cr-1 345 
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expression in smaller tumors. Mice were vaccinated at 10 and 12 weeks of age, 346 
but this did not result in difference in tumor outgrowth (data not shown) nor did 347 
it affect tumor incidence in this mouse model (Fig. 3A). Consequently, we did not 348 
observe survival benefits (Fig. 3B) until mice were sacrificed according to the 349 
ethical regulations.  At sacrifice, lungs were evaluated for the presence of 350 
metastasis. Micrometastases derived from the primary tumors can be found in 351 
the lungs within 8 weeks of primary tumor occurrence (27). 352 
Lungs from pmCR-1- and pVAX1-vaccinated mice were sectioned, stained with 353 
hematoxylin and eosin and metastatic foci enumerated.  We found that 354 
metastatic burden was significantly reduced in pmCR-vaccinated BALB-neuT 355 
mice (Fig. 3C). We observed that both the number of foci as well as metastatic 356 
size was reduced (Fig. 3C, D).   357 
 358 
Vaccination results in protective immune response targeting cancer stem cells 359 
Since targeting Cr-1 inhibits metastases, which can be caused by CSC, and Cr-1 360 
expression has previously been associated with CSC in melanoma, colon and 361 
breast cancer CSC (5,28-30). We therefore wanted to evaluate if Cr-1 vaccination 362 
elicits a protective immune response against Cr-1 expressing CSC. It has been 363 
shown that the murine mammary carcinoma cell line TUBO acquires CSC 364 
phenotypic markers when passaged 3 times as spheres (P3 TUBO cells) (21,31). 365 
Over the three passages in spheroid culture of TUBO, we observed a gradual 366 
increase in expression of Cr-1 (Fig. 4A). These TUBO P3 cells were s.c. injected in 367 
vaccinated BALB/c mice. We observed a decreased growth rate as a result of 368 
pmCR-1 vaccination. The time to reach the mean tumor size of pmCr-1 group (4 369 
mm in diameter) was significantly longer in pmCr-1- compared to pVAX1-370 
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vaccinated mice (Fig. 4B). In addition, we found that 3 out of 11 mice in the 371 
pmCr-1 group were completely tumor free more than 60 days after tumor 372 
inoculation (Fig. 4C).  In comparison, all mice in pVAX1 treatment group 373 
developed tumors within 47 days. Vaccination targeting Cr-1 also resulted in a 374 
trend towards improved survival (p=0.078) (Fig. 4D).   375 
 376 
Discussion 377 
The metastatic process of tumors is complex and until today not fully 378 
understood. Two critical cellular processes are crucial for the occurrence of 379 
metastasis, which are EMT and mesenchymal-epithelial transition (MET) (32). 380 
EMT enables cells to survive without cell-cell contact, to migrate and to 381 
extravasate from the primary tumor. At the site of distant metastasis MET is 382 
required for cells to establish metastatic colonies and grow out.  Cr-1 is 383 
expressed in cells undergoing EMT and higher expression of this protein has 384 
been found in more aggressive types of human breast cancer (12,33). 385 
We have previously reported that Cr-1 is an immunogenic antigen and that 386 
vaccination against Cr-1 results in protective anti-tumor immune responses 387 
against murine melanoma. In this model, a strong protective effect against 388 
pulmonary metastases was observed upon i.v. challenge with metastatic B16F10 389 
cells (17). It is of considerable importance to study the vaccine in a model 390 
recapitulating the complete metastatic cascade from tumor cells undergoing 391 
EMT at the primary tumor site to MET at the site of metastasis. We therefore 392 
chose to study this process in the 4T1 orthotopic breast cancer model and in 393 
Her2 transgenic BALB-neuT mice. When 4T1 cells are orthotopically injected 394 
into the mammary fat pat, they spontaneously metastasize (34,35). Similarly, the 395 
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BALB-neuT mice develop autochthonous mammary tumors that early 396 
metastasize and colonize the lungs (27). These models enable the study of EMT 397 
and MET in vivo. Due to low endogenous Cr-1 expression, we overexpressed 398 
murine Cr-1 in 4T1 cells (Suppl. Fig. 1). We observed that Cr-1 vaccination 399 
reduced metastatic burden in both the orthotopic 4T1 and the spontaneous 400 
BALB-neuT breast cancer model (Fig.1D and 3C, D). Control of the primary 401 
tumor was only seen in the Cr-1 overexpressing 4T1 model. This is in line with 402 
the lack of Cr-1 expression in the primary tumors of the BALB-neuT model 403 
(Suppl. Fig. 2). 404 
We observed that the pmCr-1 vaccination induced an anti-mCr-1 humoral 405 
response in the BALB/c mouse model, while we were not able to identify anti-406 
mCr-1 antibodies in the pVAX1 vaccinated mice (Fig. 2A). Further did the 407 
majority of Cr-1 targeting antibodies belong to the IgG2a subclass (Fig. 2B), able 408 
to bind murine activating Fcγ receptors with relatively high affinity. In view of 409 
these results, we aimed at understanding the role of NK cells in Cr-1 vaccination-410 
induced tumor control. Collectively, our data pointed at a critical role for NK 411 
mediated ADCC in pmCr-1-vaccinated mice (Fig. 2). These results are 412 
reminiscent of our earlier findings, where we have shown that Her2-vaccination 413 
in BALB/c mice initiated a humoral anti-Her2 immunity and consequently killing 414 
of Her2-positive tumor cells by NK cells (22).  In vitro cytotoxicity data 415 
demonstrated that lysis of Cr-1 expressing cells by NK cells was increased in the 416 
presence of serum from pmCr-1-vaccinated mice (Fig. 2C and D), pointing at a 417 
major role for ADCC in the tumor elimination. Hereby we were able to show one 418 
mechanism of vaccination-induced tumor elimination by NK cells. 419 
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In a previous study we have shown that anti-Cr-1 vaccination in C57Bl/6 mice 420 
induced an in vitro detectable cytotoxic T cell response (17). After vaccination, 421 
Cr-1 specific cytotoxic T cells have not been detected in vitro in BALB/c 422 
splenocytes (data not shown). Although these results do not entirely rule out a 423 
possible role for T cells in the observed in vivo tumor protection, they argue for a 424 
difference in immune response between BALB/c and C57Bl/6 mice upon DNA 425 
vaccination. In a study performed by Radkevich-Brown et al. Her2 DNA 426 
vaccination elicited a humoral immune response in Her2 transgenic BALB/c 427 
mice. In a direct comparison, Her2 vaccination induced significantly lower levels 428 
of Her2-specific antibodies in C57Bl/6 mice than in the BALB/c mice (36). The 429 
differences observed are to be explained with the genetic differences of the mice 430 
strains and can be translated to our findings in the BALB/c and C57Bl/6 mice 431 
after Cr-1 DNA vaccination (17).  432 
Cr-1 expression is potentially limited to CSC, a few cells undergoing EMT in the 433 
primary tumor, and metastasizing cells. De Castro et al. recently described Cr-1 434 
expression in EMT-like areas in the JygMC(A) breast cancer model. In contrast, 435 
no Cr-1 expression was detected in metastatic lesions in the lung (37).      436 
Vaccination against Cr-1 could potentially interrupt the metastatic process at an 437 
early stage and thereby prevent the establishment of metastases at distant sites.  438 
In CSC of several tumor types, Cr-1 expression has been confirmed (15,38,39).      439 
We have found that spheroid cultures of murine breast cancer cells, which are 440 
considered to be enriched in CSC, upregulate Cr-1 expression (Fig 4A) 441 
(21,30,31). Subcutaneously injected TUBO P3 cells grew out in all BALB/c mice 442 
within 6 weeks after injection. After vaccination against Cr-1, 27% of mice did 443 
not develop tumors (Fig. 4C). In the remaining mice, we observed a reduced 444 
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tumor growth rate (Fig. 4B and C). Immune responses induced by Cr-1 445 
vaccination specifically target Cr-1-positive CSC and control tumor burden.  446 
In patients, high levels of Cripto-1 expression in the tumor have been associated 447 
with decreased survival and could be correlated to advanced disease (12). In 448 
addition, Cripto-1 has been found in the serum of breast cancer patients, 449 
suggesting its potential function as a biomarker (40). For lung cancer, it was 450 
reported that serum levels of Cripto-1 correlated with tumor stage (41). These 451 
reported clinical findings associate increase expression of Cripto-1 with 452 
metastasis and worse survival in breast cancer patients.  453 
It is crucial for patient survival to eliminate tumor cells that can cause relapse 454 
and metastasis to potentially prolong patient survival. New therapeutic 455 
strategies, which can specifically target both CSC and metastases, have the ability 456 
to reduce the risk of relapse and disease related death in cancer patients. 457 
Immune targeting therapies have shown a great potential in treatment of 458 
metastatic diseases (42). It is crucial to identify novel immunogenic antigens that 459 
can be targeted by immunotherapies. We propose that Cripto-1 is a suitable 460 
candidate for immunotherapy in breast cancer patients, targeting a different 461 
subset of breast cancer cells than in our previous Her2 DNA vaccine clinical trial 462 
(10). We have shown that targeting Cripto-1 in breast cancer mouse models 463 
reduced metastasis and targeted CSC. For patients, a DNA vaccine targeting 464 
Cripto1 could potentially translate into increased disease free and overall 465 
survival.  466 
 467 
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Figure 1 621 
 622 
 623 
Tumor growth and metastatic spread in orthotopic 4T1mCr-1 breast cancer model 624 
 625 
Orthotopic injection of 2x105 4T1mCr-1 cells in pmCr-1- or pVAX1- vaccinated 626 
BALB/c mice. Mice were sacrificed on day 23 after tumor inoculation. A, 627 
Luciferase expression at day 14 after tumor inoculation. 4 representative mice 628 
are displayed. B, Volume of primary tumors. Mice in pVAX1 (n=5) and pmCr-1 629 
(n=5)  group were palped twice per week until experimental endpoint on day 23. 630 
Error bars represent standard deviation; * p=0.0321, **** p<0.0001 (Mann-631 
26 
 
Whitney test). C, Primary tumor weight at day 23. Error bars represent standard 632 
deviation; **** p<0.0001 (unpaired t-test). D, Single cell suspension of lung 633 
tissue was seeded in petri dish and cultured in selection medium. At day 10, 634 
colonies were fixed and counted. Metastatic index (MI) was calculated by MI= 635 
number of colonies/primary tumor weight. Error bars represent standard 636 
deviation; **** p<0.0001 (Mann-Whitney test). 637 
638 
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Figure 2 639 
 640 
Humoral response induced by pmCr-1 vaccination in BALB/c mice 641 
 642 
BALB/c mice were vaccinated with pmCr-1 or pVAX1. Two weeks after the boost 643 
vaccination, serum was collected for analysis. A, 4T1mCr-1 and 4T1 cells were 644 
incubated with serum from pmCr-1 and pVAX1. Surface binding serum 645 
antibodies were detected with anti-mIgG-FITC antibody. Cells were analyzed on 646 
flow cytometer. B, Subclasses of antibodies in pmCr-1 serum binding Cr-1 were 647 
detected with secondary anti-mIgG1-FITC, anti-mIgG2a-FITC, anti-mIgG2b-FITC. 648 
Cells were analyzed by flow cytometry.  C, NK cells cytotoxicity against 4T1mCr-649 
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1 cells in the presence of pmCr-1 or pVAX serum. Assay supernatants were 650 
harvested after 4h and 16h for analysis. D, NK cell cytotoxicity against 4T1mCr-1. 651 
Summary of 5 individual experiments after 4h co-culture at 9:1 effector to target 652 
ratio; * p=0.0158 (Paired t test). E, NK cell cytotoxicity against 4T1. Summary of 653 
5 individual experiments after 4h co-culture at 9:1 effector to target ratio.  654 
655 
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Figure 3 656 
 657 
Metastatic spread in Her2/neu driven spontaneous breast cancer model BALB-658 
neuT 659 
BALB-neuT mice were vaccinated at 10 weeks and 12 weeks with pmCr-1 or 660 
pVAX1. Mice were followed over time and sacrificed upon ethical endpoint.  A, 661 
Tumor incidence in pVAX1 (n=6 ) and pmCr-1 (n=6) vaccinated BALB-neuT 662 
mice.  B, Survival of pVAX1 (n=6) or pmCr-1 (n=6) vaccinated BALB-neuT mice.  663 
Mice were sacrificed upon ethical endpoints. C, Metastatic burden in the in 664 
pVAX1 (n=5) and pmCr-1 (n=5) mice.  Metastatic index is calculated by 665 
MI=number of foci/sum of the diameter of all primary lesions. Error bars 666 
represent standard deviation; * p=0.021 (Mann-Whitney test). D, Light 667 
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microscopy image of the lung sections after hematoxylin and eosin staining, 10x 668 
magnification.    669 
670 
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Figure 4 671 
 672 
Vaccination induced immune response is targeting breast cancer stem cells  673 
P3 TUBO cells were s.c. injected in pmCr-1 or pVAX1 immunized BALB/c mice. A, 674 
Western Blot for Cr-1 in spheroid passaged TUBO cell line. B, Tumor growth rate 675 
in pmCr-1 (n=11) and pVAX (n=11) vaccinated mice. Error bars represent 676 
standard deviation; * p=0.0453 (Mann-Whitney test). C, Individual tumor growth 677 
curves for pmCr-1 and pVAX until day 61. D, Survival curves for mice immunized 678 
with pmCr-1 or pVAX1 after s.c. challenge with TUBO P3. p=0.078 (Mantel-Cox 679 
test). 680 
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